HCPCS Level II code J0275 denotes an alprostadil urethral suppository administered under direct physician supervision in a clinical setting. This code identifies clinician-administered drug therapy for erectile dysfunction or related indications when self-administration is not applicable or allowed. Nationally, correct use of this HCPCS Level II code matters for accurate claims processing, clinical documentation, and coverage determinations tied to physician-supervised drug delivery.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, common billing considerations for clinician-administered urethral alprostadil, and operational benchmarks where available. The publication also reviews the clinical context for using an in-clinic urethral suppository versus self-administered therapies and highlights billing nuances tied to physician supervision requirements.

This summary is intended to inform billing staff, clinicians, and policy analysts about the purpose and administrative context of HCPCS Level II code J0275, typical sites of service, and the types of payer policies and documentation practices that are relevant for accurate claims submission. Data not available in the input is noted and not inferred.